Insider Purchases: Inside the Buy
Tag: Growth Stocks
🚀 Karman Space & Defense (KRMN): $1.03M Insider Buying, $1.3B Backlog & 58% Revenue Growth
Three Karman Space & Defense directors just bought roughly $1.03 million of KRMN near $37 after a brutal 70% drawdown. Meanwhile, Q2 revenue surged 58%, backlog hit $1.3 billion and guidance rose. The business is firing—but at roughly 44x forward earnings, is the stock finally cheap enough?
🤖 Upstart (UPST): $7.65M Founder Buying Meets a 30.6% Short-Squeeze Fuse 💳⚡
Upstart CEO Paul Gu and Executive Chairman Dave Girouard have bought roughly $7.65 million of UPST stock. Now revenue is growing 42%, GAAP profitability has returned—and 30.6% of the float is short. We dissect one of fintech’s most fascinating battleground stocks.
🚗 Uber (UBER): CEO’s $10M Buy, $10B Free Cash Flow, $14.8B Delivery Hero Deal & the Robotaxi Moat 🍔🤖
Uber CEO Dara Khosrowshahi just bought roughly $10 million of UBER stock near $71. Meanwhile, trailing free cash flow has topped $10 billion, the platform serves 208 million monthly consumers, and robotaxis may prove less existential threat than unexpected opportunity. We unpack the bull case, valuation, risks and an 8.67/10 FunStock Index™ score.
🩺 Alphatec (ATEC): CEO’s $1M Buy, Positive Free Cash Flow & an 11% Short-Squeeze Fuse 🦾🦴
Alphatec CEO Pat Miles just put $1.01 million of his own money into ATEC at $8.81. With positive free cash flow, improving EBITDA, Valence robotics and 11% short interest, is this battered spine-medtech stock finally reaching its turnaround moment?
💳 Klarna (KLAR): A $10M CEO Buy, 42% TMD Growth & a 75% Post-IPO Crash
Klarna has fallen roughly 75% from its post-IPO high, yet revenue rose 27%, transaction margin dollars surged 42%, and co-founder/CEO Sebastian Siemiatkowski just bought $9.95 million of KLAR. Is Wall Street pricing a broken fintech—or overlooking a rapidly evolving payments platform?
🫀 Boston Scientific (BSX): The CEO Just Bought $9 Million. Is Wall Street Missing Something?
Boston Scientific's stock has been cut nearly in half from its peak, yet the business remains fundamentally strong. With CEO Mike Mahoney buying $9 million worth of shares, a remarkably low 0.71 PEG ratio, billions in annual free cash flow, and overwhelming institutional ownership, is Wall Street overlooking one of healthcare's most attractive GARP opportunities?
🧬 Ionis Pharmaceuticals (IONS): The RNA Arbitrage — $2.1B Cash, $1M Insider Buy, and the Post-Trial Collapse
Ionis Pharmaceuticals (NASDAQ: IONS) lost billions in market value after a disappointing clinical trial—but one director immediately bought more than $1 million worth of shares. Is Wall Street missing the bigger RNA platform story? Here's the full analysis.
⚛️ Standard Nuclear (NYSE: STDN): Fascinating Technology. Speculative Stock.
Standard Nuclear may help power tomorrow's AI-driven economy, but investing isn't about buying exciting technologies at any price. We examine STDN's IPO, Decisive Point's $19 million purchase, its impressive backlog, and why patience may be the smartest move.
📐 Autodesk (ADSK): Insider Buying, 58% Free Cash Flow Growth, and the AI "AIntegration" Opportunity
Autodesk isn't trying to beat AI—it may be one of the companies best positioned to integrate it. With executives buying shares, free cash flow soaring 58%, and a surprisingly attractive PEG ratio, ADSK deserves another look.
🎨 Adobe (ADBE) Stock Analysis: Why Eli Lilly CEO David Ricks Just Bought $1.9 Million of Adobe Stock
Wall Street says AI threatens Adobe. The numbers tell a different story. Revenue keeps hitting records, AI recurring revenue has tripled, valuation has collapsed to multi-year lows, and Eli Lilly CEO David Ricks just invested another $1.9 million of his own money. Here's why Adobe may deserve another look.